Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Friday

Werewolf Therapeutics (NASDAQ:HOWL) will likely be releasing its Q1 2025 earnings data before the market opens on Friday, May 2nd. Analysts expect Werewolf Therapeutics to announce earnings of ($0.44) per share for the quarter.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. On average, analysts expect Werewolf Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $0.90 on Friday. Werewolf Therapeutics has a twelve month low of $0.60 and a twelve month high of $6.89. The stock has a market cap of $40.21 million, a P/E ratio of -0.59 and a beta of 0.48. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The business’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $1.55.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HOWL shares. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th. Finally, JMP Securities dropped their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.